Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
作者:
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);抗肿瘤药(Antineoplastic Agents);硼酸化物(Boronic Acids);白消安(Busulfan);无病生存(Disease-Free Survival);女(雌)性(Female);随访研究(Follow-Up Studies);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);男(雄)性(Male);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);骨髓摘除激动剂(Myeloablative Agonists);前瞻性研究(Prospective Studies);吡嗪类(Pyrazines);存活率(Survival Rate);移植预处理(Transplantation Conditioning)
DOI
10.1016/j.bbmt.2014.08.007
PMID
25139216
发布时间
2015-11-19
- 浏览100
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文